India, Sept. 18 -- Creative Medical Technology Holdings (CELZ), a biotechnology company developing regenerative medicine technologies, has filed a new U.S. provisional patent application to expand intellectual property protection for its Ultrasome platform. Ultrasome is a proprietary cell-free regenerative medicine platform derived from the company's umbilical cord tissue technology and is being developed for potential applications in musculoskeletal and cartilage disorders, including knee osteoarthritis.
The application seeks protection around product function rather than particle identity alone, including biological potency, product composition, manufacturing and quality-control methods, stability, delivery approaches and therapeutic app...